ClinicalTrials.gg
CompletedNCT06610487Updated Mar 2, 2026

A Study of FT1 in Healthy Adult Volunteers

A Phase 1 interventional study of FT1 and Placebo in Diarrhea Caused by Drug (Disorder), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 50 studies in Diarrhea with a site in China — 19 open to participants now, 20 under way, 3 of them phase 3. Diarrhea · China.

Enrollment
33rd of 43
60 · median 180
Started
2024
with 5 others
Phase 1
5 of 50
2 open now
Registered
34th of 50
by date

Among the 50 studies in Diarrhea with a site in China, this one is the 33rd largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2024, is one of 5 in phase 1, and was the 34th registered.

Diarrhea

880 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

19 of the 50 studies in Diarrhea with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Diarrhea studies recruiting now, 21 (46%) set no upper age limit and 23 (50%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Diarrhea with a site in China, or all of them as a file.
02

Study summary

The main aim of this clinical trial is to assess the safety of FT1 in participants aged 18 to 45 years. The main questions it aims to answer are:

  • Is FT1 safe in healthy adults? Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and active in human.

Participants will

  • Receive one subcutaneous injection or multiple injections of FT1 or placebo according to weight.
  • Visit the clinic for assessment.
Read the detailed description

This study is a first-in-human study, which is a single-center, randomized, placebo-controlled, double-blind, dose escalation clinical study, aiming to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FT1 in healthy adult volunteers.

The trial is divided into 2 parts, single-dose part and multiple-dose part. In multiple-dose part, participants will receive once weekly subcutaneous injection of FT1 for 3 weeks.

03

Conditions studied

  • Diarrhea Caused by Drug (Disorder)

Browse trials for

Keywords

  • Chemotherapy induced diarrhea
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. healthy male or female subjects aged 18 to 45 years (inclusive);
  2. Male subjects weighing ≥ 50.0kg, female subjects weighing ≥ 45kg; (BMI) in the range of 19.0-26.0 kg/m\^2 (inclusive);
  3. Voluntarily participate and sign the form;
  4. Be able to complete the trial in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. History of allergic diseases (including but not limited to asthma, urticaria, allergic rhinitis), or a history of drug allergies, or a history of allergies to the ingredients of the drug;
  2. Abnormal results of vital signs, physical examination, 12 lead examination, and laboratory tests (including blood routine, urine routine, blood biochemistry, coagulation function, thyroid function) during the screening period with clinically significance determined by the researcher;
  3. History or experiencing diseases with abnormal clinical manifestations, including but not limited to neurological/psychiatric, respiratory, cardiovascular, digestive, blood and lymphatic, urinary, endocrine, immune system diseases, or any other diseases or physiological conditions that may interfere with test results;
  4. With intestinal polyp disease or have undergone intestinal polyp surgery within 6 months before screening;
  5. Any positive results of surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody and treponema pallidum (TP) antibody test;
  6. Positive urine test results for drug abuse (including morphine, methamphetamine, ketamine, cocaine, methylenedioxymethamphetamine, tetrahydrocannabinolic acid);
  7. History of drug use or drug abuse (including the use of prohibited substances for medical use and controlled drugs);
  8. History of critical surgery within 3 months before screening or plan to undergo surgery during the trial, as well as a history of surgery that may affect drug absorption, distribution, metabolism and excretion;
  9. Participated in any clinical trial as a subject within 3 months before screening;
  10. Have donated blood or lost more than 400 mL of blood/plasma within 3 months before screening (except for physiological blood loss in women);
  11. Alcoholics (i.e. males drinking more than 28 standard units of alcohol per week and females drinking more than 21 standard units of alcohol per week, with 1 standard unit containing 14g of alcohol, such as 360mL beer or 45mL of 40% spirits or 150mL wine) or those who have frequently consumed alcohol within the previous 6 months (i.e. drinking more than 14 standard units of alcohol per week), or those who cannot abstain from alcohol during the trial, or those who have a positive alcohol breath test;
  12. Took any prescription or over-the-counter drugs, as well as any functional vitamins or herbal products within 14 days before screening;
  13. Have a long-term history of excessive consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 1 cup = 250mL)
  14. Smoked more than 5 cigarettes per day within 6 months before screening;
  15. Cannot guarantee to refrain from strenuous exercise, smoking and special diet (including grapefruit, chocolate, tea, cola, or any food or beverage containing caffeine, alcoholic beverages or other food or beverage that affects drug absorption, distribution, metabolism and excretion) from 48 hours before medication to the last blood collection;
  16. Pregnant or lactating women, or female subjects who have had unprotected sex in the past two weeks, or female subjects with positive pregnancy test; subjects (or their partners) who have fertility plans or sperm/egg donations during the entire trial period and within 6 months after the last medication, and are unwilling to take one or more measures during the trial and within 6 months after the last medication;
  17. Cannot tolerate venous puncture or have difficulty in venous blood collection;
  18. History of needle phobia or blood phobia or known severe bleeding tendency;
  19. Have special dietary requirements and cannot follow a uniform diet;
  20. The investigator believes the subject is unsuitable for participating in this clinical study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Single-dose FT1

    A single dose of FT1 will be administered, subcutaneous injection

    Drug: FT1

  • Placebo comparator
    Single-dose FT1 Placebo

    A single dose of FT1 Placebo will be administered, subcutaneous injection

    Drug: Placebo

  • Experimental
    Multiple-dose FT1

    FT1 will be administered once weekly for 3 weeks, subcutaneous injection

    Drug: FT1

  • Placebo comparator
    Multiple-dose FT1 Placebo

    FT1 Placebo will be administered once weekly for 3 weeks, subcutaneous injection

    Drug: Placebo

Interventions

  • DrugFT1

    Six dose levels will be evaluated in single-dose part, and three dose levels in multiple-dose part.

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Treatment-related Adverse Events

    To evaluate the adverse events as characterized by type, frequency, severity as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, timing, seriousness, and relationship to study therapy after administration.

    Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part

Secondary outcomes

  1. The Area Under the Curve from dosing to the time of the last measured concentration (AUC0-t)

    Pharmacokinetic parameter

    Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part

  2. Maximum plasma concentration (Cmax)

    Pharmacokinetic parameter

    Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part

  3. The half-life (t1/2)

    Pharmacokinetic parameter

    Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part

  4. Anti-drug Antibody

    Immunogenicity of FT1

    Time frame: up to 29 days in single-dose part, and up to 43 days in multiple-dose part

07

Study locations

1 site
  • Bishan Hospital of Chongqing
    Chongqing, Chongqing Municipality 402760, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2025, 11 months.

Of 23 phase 1 interventional studies under Diarrhea, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Sep 24, 2024
StartActual
Aug 20, 2024
Primary completionActual
Aug 8, 2025
CompletionActual
Aug 8, 2025
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06610487
Responsible party
Sponsor
First posted
Sep 24, 2024
Start date
Aug 20, 2024
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025
Last update
Mar 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion